{"id":5172,"date":"2024-06-10T14:12:44","date_gmt":"2024-06-10T06:12:44","guid":{"rendered":"https:\/\/regask.com\/?p=5172"},"modified":"2024-11-05T20:57:03","modified_gmt":"2024-11-05T12:57:03","slug":"chikungunya-impfstoff-zugelassen","status":"publish","type":"post","link":"https:\/\/regask.com\/de\/chikungunya-vaccine-approved\/","title":{"rendered":"EMA empfiehlt Zulassung des ersten Impfstoffs zum Schutz\u2026"},"content":{"rendered":"<p>Am 31. Mai 2024 gab die Europ\u00e4ische Arzneimittel-Agentur (EMA) ihre Empfehlung zur Zulassung von Ixchiq bekannt, dem ersten Impfstoff zum Schutz Erwachsener vor Chikungunya, einer von infizierten M\u00fccken \u00fcbertragenen Viruserkrankung.<\/p>\n<p>Diese bahnbrechende Entwicklung stellt einen wichtigen Meilenstein f\u00fcr die \u00f6ffentliche Gesundheit dar, da Chikungunya aufgrund seiner schnellen Ausbreitung und der damit verbundenen starken Gelenkschmerzen zunehmend Anlass zur Sorge gibt. Die Zulassung von Ixchiq stellt einen neuen Meilenstein im Pharma- und Gesundheitssektor dar und zielt darauf ab, die Ausbreitung dieser schw\u00e4chenden Krankheit einzud\u00e4mmen.<\/p>\n<p><strong>Wichtige Highlights:<\/strong><\/p>\n<ul>\n<li><strong>Zielgruppe:<\/strong> Der Impfstoff ist f\u00fcr die Anwendung bei Erwachsenen zugelassen, wobei der Schwerpunkt auf einer Bev\u00f6lkerungsgruppe liegt, die einem Risiko einer Chikungunya-Infektion ausgesetzt ist.<\/li>\n<li><strong>Globale Auswirkungen:<\/strong> Mit dieser Zulassung wird eine wichtige Pr\u00e4ventivma\u00dfnahme gegen eine Krankheit eingef\u00fchrt, die weltweit ausgebrochen ist, und die entscheidende Rolle der Impfung bei der Krankheitskontrolle und -pr\u00e4vention wird hervorgehoben.<\/li>\n<li><strong>Branchenkonformit\u00e4t:<\/strong> Unternehmen, die an der Produktion, Verteilung oder Verabreichung von Impfstoffen beteiligt sind, m\u00fcssen ihre Compliance- und Regulierungsrahmen aktualisieren, um diesen neuen Impfstoff zu integrieren und die Einhaltung der EMA-Richtlinien sicherzustellen.<\/li>\n<li><strong>Gesundheitsberatung:<\/strong> Anbieter und Aufsichtsbeh\u00f6rden m\u00fcssen \u00fcber die Verf\u00fcgbarkeit des Impfstoffs, die empfohlene Anwendung und m\u00f6gliche Aktualisierungen der Impfpl\u00e4ne auf dem Laufenden bleiben.<\/li>\n<li><strong>Laufende \u00dcberwachung:<\/strong> Regulierungsteams sollten au\u00dferdem weitere Forschungsarbeiten oder Aktualisierungen hinsichtlich der Wirksamkeit und Sicherheit des Impfstoffs \u00fcberwachen, da laufende Studien die Regulierungsstandards beeinflussen k\u00f6nnen.<\/li>\n<\/ul>\n<p>Die Stellungnahme wird nun an die Europ\u00e4ische Kommission weitergeleitet, die \u00fcber eine EU-weite Marktzulassung entscheiden kann. Antragsteller f\u00fcr Ixchiq ist die Valneva Austria GmbH.<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<a data-animate=\"fadeInLeft\" href=\"https:\/\/www.ema.europa.eu\/en\/news\/first-vaccine-protect-adults-chikungunya\" target=\"_blank\" class=\"button secondary is-link is-medium\" rel=\"noopener\" >\n\t\t<span>Lesen Sie den vollst\u00e4ndigen Artikel<\/span>\n\t<\/a>\n\n<p>\u00a9Dieser RegAlert wird herausgegeben von RegASK<\/p>","protected":false},"excerpt":{"rendered":"<p>Am 31. Mai 2024 gab die Europ\u00e4ische Arzneimittel-Agentur (EMA) ihre Empfehlung zur Zulassung von Ixchiq bekannt, dem ersten Impfstoff zum Schutz Erwachsener vor Chikungunya, einer Viruserkrankung, die durch infizierte M\u00fccken \u00fcbertragen wird. Diese bahnbrechende Entwicklung stellt einen wichtigen Meilenstein f\u00fcr die \u00f6ffentliche Gesundheit dar, da Chikungunya aufgrund seiner schnellen Ausbreitung ein wachsendes Problem darstellt\u2026<\/p>","protected":false},"author":39,"featured_media":3960,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[35],"tags":[247,419,421,423,425],"class_list":["post-5172","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharma-biotech-latest-insights","tag-regulation-eu-legislation","tag-vaccine","tag-chikungunya","tag-ema","tag-market-authorization"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.6 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Chikungunya Vaccine Approved by EMA | RegASK<\/title>\n<meta name=\"description\" content=\"EMA recommends approval of Ixchiq, the first vaccine to protect adults against chikungunya. Learn more about this breakthrough.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/regask.com\/de\/chikungunya-impfstoff-zugelassen\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EMA Recommends Approval of the First Vaccine to Protect Adults Against Chikungunya\" \/>\n<meta property=\"og:description\" content=\"EMA recommends approval of Ixchiq, the first vaccine to protect adults against chikungunya. Learn more about this breakthrough.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/regask.com\/de\/chikungunya-impfstoff-zugelassen\/\" \/>\n<meta property=\"og:site_name\" content=\"RegASK\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-10T06:12:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-05T12:57:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/regask.com\/wp-content\/uploads\/2022\/10\/ema-recommends-approval-of-the-first-vaccine-to-protect-adults-against-chikungunya-870x653.png\" \/>\n\t<meta property=\"og:image:width\" content=\"870\" \/>\n\t<meta property=\"og:image:height\" content=\"653\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Benoit Trouwaert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:site\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Benoit Trouwaert\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/regask.com\\\/chikungunya-vaccine-approved\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/chikungunya-vaccine-approved\\\/\"},\"author\":{\"name\":\"Benoit Trouwaert\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/c1d261e8dcf7b1c30b2c4f2c119df42d\"},\"headline\":\"EMA Recommends Approval of the First Vaccine to Protect&hellip;\",\"datePublished\":\"2024-06-10T06:12:44+00:00\",\"dateModified\":\"2024-11-05T12:57:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/chikungunya-vaccine-approved\\\/\"},\"wordCount\":282,\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/chikungunya-vaccine-approved\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/ema-recommends-approval-of-the-first-vaccine-to-protect-adults-against-chikungunya.png\",\"keywords\":[\"Regulation EU Legislation\",\"Vaccine\",\"Chikungunya\",\"EMA\",\"Market Authorization\"],\"articleSection\":[\"Pharma and Biotech\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/regask.com\\\/chikungunya-vaccine-approved\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/chikungunya-vaccine-approved\\\/\",\"name\":\"Chikungunya Vaccine Approved by EMA | RegASK\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/chikungunya-vaccine-approved\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/chikungunya-vaccine-approved\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/ema-recommends-approval-of-the-first-vaccine-to-protect-adults-against-chikungunya.png\",\"datePublished\":\"2024-06-10T06:12:44+00:00\",\"dateModified\":\"2024-11-05T12:57:03+00:00\",\"description\":\"EMA recommends approval of Ixchiq, the first vaccine to protect adults against chikungunya. Learn more about this breakthrough.\",\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/regask.com\\\/chikungunya-vaccine-approved\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/regask.com\\\/chikungunya-vaccine-approved\\\/#primaryimage\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/ema-recommends-approval-of-the-first-vaccine-to-protect-adults-against-chikungunya.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/ema-recommends-approval-of-the-first-vaccine-to-protect-adults-against-chikungunya.png\",\"width\":1600,\"height\":1200,\"caption\":\"New Vaccine To Protect People In The Eu And Worldwide Against Dengue\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/regask.com\\\/#website\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"name\":\"RegASK\",\"description\":\"The Regulatory AI Operating System for High-Performing Teams\",\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/regask.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/c1d261e8dcf7b1c30b2c4f2c119df42d\",\"name\":\"Benoit Trouwaert\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Chikungunya-Impfstoff von der EMA zugelassen | RegASK","description":"Die EMA empfiehlt die Zulassung von Ixchiq, dem ersten Impfstoff zum Schutz Erwachsener vor Chikungunya. Erfahren Sie mehr \u00fcber diesen Durchbruch.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/regask.com\/de\/chikungunya-impfstoff-zugelassen\/","og_locale":"de_DE","og_type":"article","og_title":"EMA Recommends Approval of the First Vaccine to Protect Adults Against Chikungunya","og_description":"EMA recommends approval of Ixchiq, the first vaccine to protect adults against chikungunya. Learn more about this breakthrough.","og_url":"https:\/\/regask.com\/de\/chikungunya-impfstoff-zugelassen\/","og_site_name":"RegASK","article_publisher":"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","article_published_time":"2024-06-10T06:12:44+00:00","article_modified_time":"2024-11-05T12:57:03+00:00","og_image":[{"width":870,"height":653,"url":"https:\/\/regask.com\/wp-content\/uploads\/2022\/10\/ema-recommends-approval-of-the-first-vaccine-to-protect-adults-against-chikungunya-870x653.png","type":"image\/png"}],"author":"Benoit Trouwaert","twitter_card":"summary_large_image","twitter_creator":"@ASKRegASK","twitter_site":"@ASKRegASK","twitter_misc":{"Written by":"Benoit Trouwaert","Est. reading time":"2\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/regask.com\/chikungunya-vaccine-approved\/#article","isPartOf":{"@id":"https:\/\/regask.com\/chikungunya-vaccine-approved\/"},"author":{"name":"Benoit Trouwaert","@id":"https:\/\/regask.com\/#\/schema\/person\/c1d261e8dcf7b1c30b2c4f2c119df42d"},"headline":"EMA Recommends Approval of the First Vaccine to Protect&hellip;","datePublished":"2024-06-10T06:12:44+00:00","dateModified":"2024-11-05T12:57:03+00:00","mainEntityOfPage":{"@id":"https:\/\/regask.com\/chikungunya-vaccine-approved\/"},"wordCount":282,"publisher":{"@id":"https:\/\/regask.com\/#organization"},"image":{"@id":"https:\/\/regask.com\/chikungunya-vaccine-approved\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2022\/10\/ema-recommends-approval-of-the-first-vaccine-to-protect-adults-against-chikungunya.png","keywords":["Regulation EU Legislation","Vaccine","Chikungunya","EMA","Market Authorization"],"articleSection":["Pharma and Biotech"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/regask.com\/chikungunya-vaccine-approved\/","url":"https:\/\/regask.com\/chikungunya-vaccine-approved\/","name":"Chikungunya-Impfstoff von der EMA zugelassen | RegASK","isPartOf":{"@id":"https:\/\/regask.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regask.com\/chikungunya-vaccine-approved\/#primaryimage"},"image":{"@id":"https:\/\/regask.com\/chikungunya-vaccine-approved\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2022\/10\/ema-recommends-approval-of-the-first-vaccine-to-protect-adults-against-chikungunya.png","datePublished":"2024-06-10T06:12:44+00:00","dateModified":"2024-11-05T12:57:03+00:00","description":"Die EMA empfiehlt die Zulassung von Ixchiq, dem ersten Impfstoff zum Schutz Erwachsener vor Chikungunya. Erfahren Sie mehr \u00fcber diesen Durchbruch.","inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/regask.com\/chikungunya-vaccine-approved\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/regask.com\/chikungunya-vaccine-approved\/#primaryimage","url":"https:\/\/regask.com\/wp-content\/uploads\/2022\/10\/ema-recommends-approval-of-the-first-vaccine-to-protect-adults-against-chikungunya.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2022\/10\/ema-recommends-approval-of-the-first-vaccine-to-protect-adults-against-chikungunya.png","width":1600,"height":1200,"caption":"New Vaccine To Protect People In The Eu And Worldwide Against Dengue"},{"@type":"WebSite","@id":"https:\/\/regask.com\/#website","url":"https:\/\/regask.com\/","name":"RegASK","description":"Das regulatorische KI-Betriebssystem f\u00fcr leistungsstarke Teams","publisher":{"@id":"https:\/\/regask.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/regask.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/regask.com\/#\/schema\/person\/c1d261e8dcf7b1c30b2c4f2c119df42d","name":"Benoit Trouwaert"}]}},"_links":{"self":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/posts\/5172","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/users\/39"}],"replies":[{"embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/comments?post=5172"}],"version-history":[{"count":0,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/posts\/5172\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/media\/3960"}],"wp:attachment":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/media?parent=5172"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/categories?post=5172"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/tags?post=5172"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}